Regarding the effect of specific HIF-1α and HIF-2α inhibition on HCC tumorigenesis, preventive treatment did not inhibit or slow down tumor development in our HCC mouse model, as macroscopic lesions were present in 100% of the ASO-treated mice and furthermore, were more numerous compared to the scrambled ASO treatment group. The gene discussed is HIF1A; the disease is hepatocellular carcinoma.